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The majority of the human genome is transcribed, even though only 2% of transcripts
encode proteins. Non-coding transcripts were originally dismissed as evolutionary junk
or transcriptional noise, but with the development of whole genome technologies, these
non-coding RNAs (ncRNAs) are emerging as molecules with vital roles in regulating gene
expression. While shorter ncRNAs have been extensively studied, the functional roles of
long ncRNAs (lncRNAs) are still being elucidated. Studies over the last decade show that
lncRNAs are emerging as new players in a number of diseases including cancer. Potential
roles in both oncogenic and tumor suppressive pathways in cancer have been elucidated,
but the biological functions of themajority of lncRNAs remain to be identiﬁed. Accumulated
data are identifying the molecular mechanisms by which lncRNA mediates both structural
and functional roles. LncRNA can regulate gene expression at both transcriptional and
post-transcriptional levels, including splicing and regulating mRNA processing, transport,
and translation. Much current research is aimed at elucidating the function of lncRNAs in
breast cancer and mammary gland development, and at identifying the cellular processes
inﬂuenced by lncRNAs. In this paper we review current knowledge of lncRNAs contributing
to these processes and present lncRNA as a new paradigm in breast cancer development.
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INTRODUCTION
Ribonucleic acids were long thought to act mainly as carriers of
genetic information between DNA and the protein-synthesizing
machinery of the cell. Whole genome technology, including deep
sequencing and microarray analyses, has demonstrated that cod-
ing regions constitute only 2%of the human genome. On the other
hand, 70–90% of the genome is transcribed (Bertone et al., 2004;
Carninci et al., 2005; Birney et al., 2007; Kapranov et al., 2010;
Djebali et al., 2012). Initially regarded as ‘junk’, these transcripts
have been found to possess many regulatory roles and represent a
largely unexplored area of cell biology.
Non-coding RNAs (ncRNAs) are deﬁned as those RNAs
which are transcribed from the genome but do not encode pro-
teins. They are divided into two broad classes based on their
function: housekeeping and regulatory. Housekeeping ncRNAs
include ribosomal, transfer, small nuclear, and small nucleolar
RNAs (snoRNAs). These ncRNAs are constitutively expressed
and crucial to the operation of vital cellular functions. Regu-
latory ncRNAs are differentially expressed according to tissue
and stage of development or disease process. These regula-
tory ncRNAs are divided into two broad classes based on their
size. The ﬁrst class of regulatory ncRNAs comprises short tran-
scripts <200 nt long and includes microRNA (miRNA), small
interfering RNA (siRNA), piwi interacting RNA (piRNA), tran-
scription initiation RNA (tiRNA), and small cajal body-speciﬁc
RNA (scaRNA). They control a number of developmental and
physiological pathways and have been shown to be deregulated
in disease processes (Mattick and Makunin, 2006; Carthew and
Sontheimer, 2009). The second class of regulatory ncRNAs is
long ncRNAs (lncRNA), which is deﬁned as those transcripts
>200 nt. Despite making up the majority of the human tran-
scriptome, they were initially dismissed as products of leaky
transcription or evolutionary noise due to their lack of open
reading frames and poor sequence conservation. However, lncR-
NAs have now been found to display key characteristics that
conﬁrm their roles as functional molecules, and a signiﬁcant
number of papers has been published in recent years focus-
ing on their function in normal development and disease. They
are mainly transcribed by RNA polymerase II and the genomic
loci of many of them contain chromatin marks, consistent with
those of transcribed genes, at their promoters and gene bod-
ies such as H3K9ac, H3K4me3, and H3K36me3. They are also
frequently polyadenylated and undergo splicing of exons, demon-
strating that they require post-transcriptional processing to form
mature transcripts. Furthermore, lncRNA expression is regulated
by well characterized transcription factors (reviewed in Guttman
and Rinn, 2012).
In general, lncRNAs show poor sequence conservation, due to
their rapid evolution, but display conserved tissue speciﬁcity and
function (Necsulea et al., 2014). Recent work has provided infor-
mation on the origin and evolution of lncRNAs, suggesting that
lncRNAemergede novo from transposable elements or non-exonic
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sequences (Derrien et al., 2012; Kapusta et al., 2013). Sequences
conserved between different species might be expected to show
conserved functions, but a recent study has shown signiﬁcant
differences in stem cell-speciﬁc transcription factor binding sites
between mouse and human (Odom et al., 2007). This observation
suggests that mouse models cannot always be used for studying
human lncRNA. Conversely, many lncRNAs display conserved
structure between different species while having poorly conserved
sequences (Torarinsson et al., 2006). These features of lncRNAs
support the hypothesis that they perform biologically robust
functions.
Long ncRNAs are further divided into several classes based
on their genomic orientation as illustrated in Figure 1 (Ponting
et al., 2009). Despite their abundance, the functions of the major-
ity of lncRNAs have yet to be elucidated. Studies of lncRNA
mechanism have revealed extensive variety in their function.
LncRNAs can act as transcriptional regulators, acting either in
cis to regulate nearby genes, or in trans to regulate distal genes
(Osato et al., 2007; Wang and Chang, 2011; Bak and Mikkelsen,
2014).
The roles of lncRNA in transcription regulation, mRNA pro-
cessing, and mRNA maturation are depicted in Figures 2A–D.
LncRNAs have a broad role in epigenetic control that goes beyond
gene regulation at the transcriptional level. Most lncRNA species
were previously thought to be restricted to the nucleus, but recent
studies have found that a larger proportion than expected is
located in the cytoplasm (van Heesch et al., 2014), suggesting post-
transcriptional gene regulation, protein shuttling, and localization
of proteins and transcripts (Figures 2E–G). A large number of
lncRNAs associate with actively translating ribosomes (Guttman
et al., 2013), indicating that lncRNA regulation of translation may
be a common phenomenon, although the exact mechanisms are
yet to be understood.
Although only a few lncRNAs have been studied in detail,
their characteristic spatial and temporal expression patterns indi-
cate that they play signiﬁcant but diverse roles in development
(Guttman et al., 2011; Ng et al., 2012; Pauli et al., 2012). Fur-
thermore, numerous studies have shown altered expression of
lncRNAs in cancer cells compared to normal tissues (Perez et al.,
2007; Du et al., 2013; Qiu et al., 2013), indicating that deregulation
of these lncRNAs can facilitate disease progression. This reviewwill
explore, in particular, the role of lncRNAs in breast development
and cancer.
LncRNAs AS KEY REGULATORY MOLECULES IN
DEVELOPMENT AND CANCER
Development of an organism is a complex process, requiring ﬁnely
regulated gene expression to determine the precise function and
architecture of differentiated tissues. Widespread transcription
of the human genome and the emergence of lncRNAs as reg-
ulatory molecules suggest that development is regulated not
only by proteins but also by an expanded network coordinated
by RNAs (reviewed in Mattick, 2007). Microarray analyses of
embryonic stem cells have revealed many differentially expressed
lncRNAs during induced differentiation, conﬁrming their key role
in embryonic stem cell development (Dinger et al., 2008). Several
of these lncRNAs are transcribed from regions near develop-
mental genes, indicating a complex relationship between protein
coding genes and non-protein coding genes in ﬁne tuning devel-
opment (Dinger et al., 2008). Systematic knockdown of lncRNAs
in mouse embryonic stem cells has been shown to have major
effects on gene expression patterns, leading to loss of pluripo-
tency and loss of repression of lineage commitment programs.
Additionally, the majority of lncRNAs examined interact with
transcription factors associated with pluripotency, and ∼30%
interact with chromatin (Guttman et al., 2011). The expression
of pseudogenes of embryonic transcription factors could facilitate
cancer progression. For example, Oct4 has four related pseu-
dogenes that are found to be expressed in glioma and breast
cancer, while Oct4 is not expressed (Zhao et al., 2011). Such
interactions suggest that lncRNAs act as components of net-
works that include established pluripotency factors and DNA to
maintain the undifferentiated replicative state of embryonic stem
cells. Chromosome architecture and epigenetic memory are reg-
ulated by lncRNAs, which recruit histone modifying complexes
and DNA methyltransferases to certain loci, maintaining cor-
rect gene expression (reviewed in Mattick, 2007; Amaral et al.,
2008).
Alterations of lncRNAs involved in cell homeostatic processes
such as cell cycle, DNA damage response, survival, proliferation,
FIGURE 1 | Schematic showing genomic organization of different
lncRNAs. The DNA strands are shown in black and gray lines. The black
and white boxes represent exons of protein coding and lncRNA genes,
respectively. LncRNAs are classiﬁed as sense (e.g., Intronic or
overlapping) or antisense, reﬂecting the way they overlap with protein
coding genes in the same or opposite direction, respectively. The diagram
shows that lncRNAs can be antisense to protein coding (antisense
lncRNA) or originate from introns of protein coding genes either as
by-products of mRNA or as independent transcripts (intronic lncRNA,
sense lncRNA). LncRNA also can be transcribed from intergenic regions
of the genome (lincRNA). LncRNA genes can overlap the protein-coding
genes (overlapping transcript).
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FIGURE 2 | Schematic illustrating the functions of lncRNAs.
(A) LncRNAs (e.g., HOTAIR) can suppress transcription by interacting
with PRC1 and PRC2 complexes as well as with other chromatin
modifying proteins, maintaining heterochromatin status and suppressing
transcription (reviewed in Gibb et al., 2011; upper panel). Trithorax
complexes also can interact with lncRNA (e.g., HOTTIP ) and induce
transcription (lower panel; reviewed in Jobe et al., 2012). (B) LncRNAs
are proposed to be transcribed at enhancer regions and can function in
the establishment and maintenance of enhancer–promoter looping and
activation of gene expression (Orom and Shiekhattar, 2013). (C) LncRNAs
such as MALAT1 can regulate alternative splicing by interacting with the
spliceosomal machinery (Tripathi et al., 2013). (D) Speciﬁc lncRNAs are
transcribed and bind to and titrate away protein factors. Decoy lncRNAs
can bind to protein factors such as transcription factors and chromatin
modiﬁers. This leads to broad changes in transcriptomes. (E) Intronic
regions of many lncRNAs host snoRNAs. The snoRNAs derived from
these lncRNAs remain in the nucleus while the spliced transcript can
move to the cytoplasm and bind either to polysomes or to other
proteins (Smith and Steitz, 1998). (F) LncRNAs can bind to miRNAs to
sequester them and inactivate their repressive functions (reviewed in
Gibb et al., 2011). (G) Many lncRNAs are associated with polysomes (van
Heesch et al., 2014), while the mechanisms of many are yet to be
identiﬁed, antisense lncRNAs such as UCHL1AS regulate the translation
of associated mRNAs. (H) Decoy lncRNAs such as GAS5 are present in
both in the cytoplasm and the nucleus: GAS5 translocates from the
cytoplasm into the nucleus with glucocorticoid receptor in response to
dexamethasone (Kino et al., 2010). TF, transcription factor; RP, RNA
polymerase; E1, exon1.
and migration have been identiﬁed in carcinogenesis. Multiple
lncRNAs regulate or are regulated by key cancer pathways, such as
the p53pathway, amaster regulator of cell cycle and survival. These
include lincRNA p21 and PANDA, which are upregulated upon
DNAdamage andare induced in ap53-dependentmanner (Huarte
et al., 2010). PANDA interacts with the transcription factor NF-YA
to limit expression of proapoptotic genes (Hung et al., 2011). Thus,
p53 protein not only induces the activity of lncRNAs to mediate
its effects, but is itself regulated by lncRNAs. MEG3 regulates the
activity of p53 by facilitating p53 binding and activation of p53
target gene promoters and inhibiting cellular proliferation (Zhou
et al., 2007). LncRNAs affect every hallmark of cancer progres-
sion (reviewed in Gutschner and Diederichs, 2012) highlighting
the shift from a solely proteomic view of tumor biology to one
that includes an extensive network of lncRNAs. Here the roles
of lncRNAs involved in mammary gland development and the
nature of their deregulation in breast cancer development are
discussed.
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ROLE OF lncRNAS IN BREAST DEVELOPMENT AND CANCER
Most organs develop before or around birth, but the mammary
gland begins its development in the embryo and continues its
growth and differentiation in puberty and adult life (Smith et al.,
2012). Mammary gland development in the embryo occurs during
mid-gestation and remains quiescent until puberty in which there
is further development of the ducts. During pregnancy, the breast
tissue undergoes further expansion and branching, and lumi-
nal cells rapidly proliferate and differentiate to milk-secreting
alveolar cells. These changes underlie the production of milk
during lactation. Cessation of lactation is accomplished by invo-
lution, in which the breast tissue undergoes extensive apoptosis to
return to the quiescent pre-pregnancy state (Watson and Khaled,
2008).
Breast development is orchestrated by a series of genes that
regulate these different cellular processes. Alterations to genes
encoding growth factors, nuclear transcription factors, cell cycle
regulatory proteins and tumor suppressor proteins have been sug-
gested to create favorable conditions to allow the outgrowth of
cells. A major focus in breast cancer research is to understand how
normal breast epithelium is transformed into malignant epithe-
lium. With the advent of genome-wide sequencing, it became
apparent that it is not solely genetic changes that contribute to
breast cancer. Epigenetic changes also play a major part in alter-
ing gene expression in such a way as to contribute to cancer
(Jones and Baylin, 2007). The role of coding genes in the regu-
lation of breast development is well established (Hennighausen
and Robinson, 2001; Anderson et al., 2007; Lim et al., 2010),
but less researched is the role of lncRNAs. Large scale microar-
ray analyses using mouse mammary gland RNA from different
stages of mammary gland development (Askarian-Amiri et al.,
2011), tiling arrays (Perez et al., 2008), and transcriptome pro-
ﬁling (Maruyama et al., 2012) of normal tissues compared to
breast cancer tissues, have revealed several lncRNAs which are
aberrantly expressed in neoplastic tissues. We describe several
lncRNAs that have been implicated in breast cancer devel-
opment, and describe molecular mechanisms by which they
may contribute to normal development and cancer progression
(Figure 3).
CHROMATIN REMODELING COMPLEXES
Of those lncRNAs with identiﬁed mechanisms, it is apparent that
many function as regulators of transcription through chromatin
regulation. These lncRNAs act as scaffolds, interacting with target
genes and recruiting factors such as histone modifying com-
plexes for gene silencing (reviewed in Rinn and Chang, 2012).
The most commonly identiﬁed histone modifying complexes that
lncRNAs interact with are polycomb group proteins. PcG pro-
teins form multisubunit complexes; the best characterized are
polycomb repressor complex 1 (PRC1) and polycomb repressor
complex 2 (PRC2), which modify histones by inducing repres-
sive chromatin marks. PRC1 catalyzes ubiquitination of lysine
119 on histone 2A (H2AUb1) while PRC2 methylates lysine 27
on histone 3 (H3K27me2/3). PRC2 is required for the initial
targeting of speciﬁc gene silencing, whereas PRC1 maintains
the gene silencing initiated by PRC2 (Morey and Helin, 2010).
LncRNAs also interact with other chromatin modifying com-
plexes, such as the LSD1–CoREST complex, which mediates the
removal of H3K4 mono and dimethylation, a chromatin mark
associated with gene activation (Rinn et al., 2007). Other chro-
matinmodifying complexes withwhich lncRNAs associate include
G9a (Nagano et al., 2008; Pandey et al., 2008), a H3K9 methyl-
transferase, and MLL1 (Bertani et al., 2011; Wang et al., 2011), a
histone methyltransferase, which associates with activating tritho-
rax complex 1. Through interacting with chromatin modifying
complexes, lncRNAs act as guides to target speciﬁc gene regions
to modify transcription either in cis or trans (Wang and Chang,
2011). This may be the predominant method in which lncR-
NAs exert their function, as global analyses have found that a
large number of lncRNAs bind to PRC2 and LSD1 (Khalil et al.,
2009).
This mechanism of gene regulation by lncRNAs ensures that
appropriate genes are switched on or off. Several lncRNAs involved
in cancer, including breast cancer, have been shown to pro-
mote tumorigenesis by inappropriately silencing genes through
deregulated interactions with histone modifying complexes.
PREGNANCY INDUCED NON-CODING RNA (PINC )
Pregnancy induced non-coding RNA (PINC) was identiﬁed ini-
tially in the rat mammary gland and exhibits conserved synteny
in the genomes of other mammals. It is differentially expressed
as pregnancy progresses (Ginger et al., 2006), highly expressed
in the alveolar cells during pregnancy, but declines during the
transition from late pregnancy to early lactation, in which the
mammary epithelium terminally differentiates to form milk pro-
ducing cells, and it is again elevated during involution. PINC
FIGURE 3 | List of lncRNAs reported in this review based on their localization, function, and expression pattern.The function of each lncRNA is above
each box. The red and black represent the genes upregulated and downregulated respectively in breast cancer.
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inhibits differentiation, and when it is expressed at low levels,
mammary cells are able to undergo differentiation (Shore et al.,
2012).
Mouse PINC (mPINC) may exert these effects on the mam-
mary gland by regulating cell cycle progression. In HC11 cells,
mPINC relocates from the nucleus to the cytoplasmas the cell cycle
progresses (Ginger et al., 2006), indicative of a role in nuclear–
cytoplasmic signal transduction or shuttling. PINC interacts with
retinoblastoma associated protein 46 (RbAp46), a component of
PRC2, suggesting that PINC may exert its role in differentiation
through modiﬁcation of chromatin and that it acts to repress gene
expression. Several potential target genes, known to be involved in
mammary gland development, have been identiﬁed, and encode
members of the Wnt and Notch signaling pathways (Shore et al.,
2012). The role of PINC in human mammary gland development
and breast cancer has yet to be ascertained.
HOX TRANSCRIPT ANTISENSE RNA (HOTAIR )
HOX transcript antisense RNA (HOTAIR) is upregulated in a
number of different cancers, including breast (Gupta et al., 2010),
colorectal (Kogo et al., 2011), hepatocellular (Geng et al., 2011),
and gastrointestinal stromal tumors (Niinuma et al., 2012). In
breast cancer, HOTAIR expression is upregulated in both primary
and metastatic tumors, and its expression in primary tumors is
strongly correlated with later metastases, patient prognosis, and
death (Gupta et al., 2010).
HOTAIR is transcribed in an antisense orientation from the
HOXC locus. It acts in trans as a repressor of the HOXD locus by
recruiting PRC2, leading to trimethylation of H3K27 and subse-
quent transcriptional silencing. The bordering regions of HOXD
are bound by CoREST/REST repressor complexes, which con-
tain the H3K4me2-speciﬁc LSD1 demethylase and also maintain
appropriate silencing of HOXD. HOTAIR binds to LSD1 at its
3′ domain, whereas the 5′ domain binds to EZH2 or SUZ12,
components of the PRC2. It acts bifunctionally as a scaffold that
bridges these two repressor complexes. This results in coordinate
binding to their target genes for coupled chromatin remodeling
(Tsai et al., 2010). Upregulation of HOTAIR leads to genome-
wide reprogramming of the PRC2 occupancy pattern from that
of breast epithelial cells to that resembling embryonic and neona-
tal ﬁbroblasts, as well as altered gene expression, that includes
the silencing of tumor suppressor genes JAM2 and PCDH (Gupta
et al., 2010).
The promoter of HOTAIR contains multiple functional estro-
gen response elements near the transcription start site, and is
transcriptionally induced by estrogen, while repressed by tamox-
ifen. A number of estrogen receptor coregulators also bind to
the HOTAIR promoter region upon treatment with estrogen such
as CBP/p300 and histone methyltransferases MLL1 and MLL3.
In the basal state, HOTAIR is repressed, but estradiol treatment
causes exchange of repressive molecules for transcriptional acti-
vators and coregulators, leading to gene activation (Bhan et al.,
2013).
An alternative mechanism for HOTAIR’s function in breast
cancer is through competitive binding with tumor suppressor
genes. BRCA1 is an important breast cancer tumor suppressor
gene that functions in DNA damage responses. BRCA1 binds to
EZH2, a component of the PRC2 in mouse and human mam-
mary epithelial cells, acting as a competitive inhibitor of HOTAIR.
Reduced BRCA1 expression, which is often observed in cancer
allows HOTAIR to bind to PRC2, promoting reprogramming
of breast epithelial cells to aggressive cancer cells (Wang et al.,
2013).
XIST
One of the best studied lncRNAs is XIST, transcribed from the
X inactivation center of the X chromosome that is destined to
be inactivated in female mammals (Brown et al., 1991), from
whence it spreads along the X chromosome to promote hete-
rochromatin formation andultimately formation of theBarr body.
This mechanism ensures dosage compensation with males. Loss of
the Barr body is observed consistently in female cancers including
breast cancer. Under normal conditions, two active X chromo-
somes are incompatible with human life, but activation of both
X chromosomes may be advantageous to the cancer cell, as the X
chromosome contains several oncogenes. XIST expression is lost
in female cancers including breast, ovarian, and cervical cancer
(reviewed in Froberg et al., 2013). XIST itself is under regulation
by several lncRNAs such as Tsix (negatively; Leeb et al., 2009) and
Jpx (positively; Tian et al., 2010), highlighting the complexity of
the network by which lncRNAs function to induce X chromosome
inactivation.
The mechanism by which XIST functions in breast cancer is
controversial, with some studies showing interaction of the tumor
suppressor gene BRCA1 with XIST, and that loss of BRCA1 is
associated with loss of XIST. Upon reactivation of BRCA1, XIST
staining by in situ hybridization was restored (Ganesan et al.,
2002, 2004). Other studies have shown that XIST and BRCA1
do not physically co-localize and that reintroduction of BRCA1
did not reactivate XIST staining. The same discrepancy of XIST
and BRCA1 is observed in human breast tumors, with some stud-
ies showing concurrent loss of both BRCA1 and XIST in highly
aggressive breast cancers (Richardson et al., 2006) while other
studies of breast cancer tissue from patients with germline BRCA1
mutations show expression of XIST in a signiﬁcant number of
samples (Vincent-Salomon et al., 2007). Whether XIST interacts
with BRCA1 to regulate cancer progression or if genetic instability
due to loss of BRCA1 expression is responsible for reduced XIST
expression is yet to be clariﬁed.
PROTEIN DECOYS
The ability of lncRNAs to form complex secondary structures gives
them the capacity to present a diversity of interfaces for binding
to proteins. LncRNAs may recruit or organize proteins as evi-
denced by their roles as chromatin modiﬁers, or act as decoys
which inhibit protein functions. One such lncRNA, GAS5 which
is discussed below, functions as a protein decoy by binding to the
glucocorticoid receptor (GR) and preventing it from interacting
with the glucocorticoid response element (GRE; Kino et al., 2010;
Figure 2H).
BC200
BC200 is normally selectively expressed in brain tissue and germ
cells. It exhibits a high degree of tissue speciﬁcity in the brain,
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showing expression in somatodendritic domains in a subset of
neurons but not in other somatic cells. BC200 functions to repress
translation through its oligo(A) rich region which is able to bind
polyA binding protein (PABP), so that it is no longer able to bind
translation initiation factors (Kondrashov et al., 2005).
This neuronal speciﬁcity is lost in a number of tumors, includ-
ing breast cancer (Chen et al., 1997). BC200 expression is highly
elevated in invasive tumors but not in benign tumors. Further-
more, highBC200 expression is associatedwith highnuclear grade,
an indicator of aggressive cancer cell behavior. Not all DCIS lesions
progress to invasive disease, andBC200 could be used as a prognos-
tic indicator to assess the invasive potential in early breast tumors
to ensure appropriate treatment is given (Iacoangeli et al., 2004).
STEROID RECEPTOR RNA ACTIVATOR 1 (SRA1)
Steroid receptor RNA activator 1 (SRA1) acts as a nuclear coac-
tivator for a number of steroid hormone receptors, including the
estrogen, progesterone (Lanz et al., 1999), and androgen receptors
(Kurisu et al., 2006). It also coregulates the activity of a number
of non-steroid receptors and transcription factors. It was discov-
ered as a functional lncRNA which can be alternatively spliced to
form a protein coding gene, called steroid receptor RNA activator
protein (SRAP) which has unique functions as well as overlapping
functions to SRA1 in modulating gene expression. SRA1 forms a
stem-loop structure, which enables it to bind to multiple proteins
including steroid receptors, transcription factors, RNA helicases,
and other molecules involved in adipogenesis, myogenesis, and
adrenal gland gene function (reviewed in Colley and Leedman,
2011).
A mouse model was generated to investigate the relationship
between SRA1 and mammary gland development. No change was
observed during early development but in mature virgin trans-
genic mice, activation of SRA1 led to an increase in proliferation
and differentiation, and to abnormally early development of the
ductal epithelium. SRA1 also regulates cell death, as in these trans-
genic mice, epithelial hyperplasia was accompanied by increased
apoptosis (Lanz et al., 2003). These results underline a relation-
ship between the roles of SRA1 and of steroid hormone receptors
in mammary gland development, as well as a role in regulating
apoptosis to maintain healthy breast function. SRA1 expression is
elevated in a number of estrogen responsive tumors such as ovar-
ian (Hussein-Fikret and Fuller, 2005) and breast cancer (Leygue
et al., 1999; Murphy et al., 2000). SRA1 is able to activate the estro-
gen receptor to increase proliferation and its expression could be
indicative of tumor grade or type, as higher expressionof SRA1was
observed in ER-α-positive/PR-negative tumors compared to ER-
α-positive/PR-positive tumors (Leygue et al., 1999), but although
SRA1 enhances mammary gland proliferation, it is insufﬁcient
for malignant transformation (Lanz et al., 2003). Although the
literature suggests that SRA1 promotes cancer progression, a com-
plex interplay with steroid hormone receptor activation and other
oncogenic proteins is likely to be required to drive malignant
growth.
MicroRNA–lncRNA INTERACTIONS
MicroRNAs are small regulatory RNAs of about 22 nt that reg-
ulate gene expression by binding to speciﬁc mRNAs through
sequence complementarity, and targeting them for degradation
by the RNA-induced silencing complex (RISC). MiRNAs are reg-
ulated transcriptionally and also post-transcriptionally by a class
of lncRNAs known as competitive endogenous RNAs (ceRNAs)
that act as sponges or decoys to titrate miRNAs away from their
target mRNAs and buffer their activity (Bak and Mikkelsen, 2014).
Several ceRNAs such HULC in liver cancer cells sequester miR-
372 (Wang et al., 2010) and PTENP1 sequesters PTEN-targeting
miRNAs through similarities in miRNA binding sites in prostate
cancer cells (Poliseno et al., 2010). Non-protein coding regions
of the genome contain a high proportion of miRNA targets, and
as lncRNAs are often found in intergenic and intronic regions
of the genome, could be frequently targeted by miRNAs (Clark
et al., 2014). Alignment of several other genes and their cor-
responding ceRNAs shows that miRNA binding sites are well
conserved indicating thatmiRNA–lncRNA interactions playmajor
roles in biological processes (Poliseno et al., 2010). MiRNAs can
target the exons of coding regions and exon–exon junctions,
enabling selective targeting of particular splice variants (Tay et al.,
2008).
Long ncRNAs, ceRNAs, and miRNAs form regulatory net-
works across the transcriptome, communicating with each other
to regulate gene expression. This includes short motifs known as
pyknons, which are a subset of variable length patterns. Pyknons
are conserved in the genome, and are found in coding and non-
coding regions, but mostly in 3′UTRs. Pyknon sequences contain
40% of known miRNA sequences, suggesting that they regulate
miRNA function (Rigoutsos et al., 2006). Different sets of pyknons
are associated with disease-associated single nucleotide polymor-
phisms, suggesting that susceptibility to disease is due to genome
wide regulation of miRNAs (Glinsky, 2009).
While some established miRNA–lncRNA interaction sites are
conserved to various extents, others lack conservation despite
showing conﬁrmed functions (Alaei-Mahabadi and Larsson,
2013). It may potentially be difﬁcult to extrapolate gene effects
in animal models to human diseases. To address this challenge,
it must ﬁrst be demonstrated that miRNA binding sites in lncR-
NAs are conserved before assuming cross-species efﬁcacy (Jackson
and Levin, 2012). Paci et al. (2014) have used computational
approaches to assess whether speciﬁc lncRNAs function as miRNA
decoys in normal and invasive breast epithelium. In normal breast
tissue, a complex regulatory network of miRNA-mediated inter-
actions exist to bridge target mRNAs and lncRNAs, and this is
missing in tumor samples. However, the role of miRNA-decoys in
breast cancer remains to be validated with functional studies.
SnoRNA HOSTS
Small nucleolar RNAs are a well characterized class of small ncR-
NAs that predominantly localize to the nucleolus and act there as
guides for post transcriptional modiﬁcation of ribosomal RNAs.
These snoRNAs bind modifying proteins, then hybridize with
speciﬁc rRNA sequences, facilitating rRNA modiﬁcation. Two
major classes of snoRNAs are involved in two different types of
post-transcriptional modiﬁcation: the C/D box snoRNAs which
deﬁne sites for 2′O ribose methylation, and the H/ACA box
snoRNAs which deﬁne the sites for pseudo-uridylation (Williams
and Farzaneh, 2012).
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Genetic searches for cancer genes have revealed that aside from
their housekeeping function for rRNA modiﬁcations, a number
of snoRNAs are also deregulated in cancer. An example is the
snoRNA U50, a candidate tumor suppressor gene. It is downregu-
lated and frequently mutated in prostate and breast cancer (Nallar
and Kalvakolanu, 2013).
Small nucleolar RNAs are often located within the introns of
protein coding and lncRNA genes. The latter may have indepen-
dent functions, such as involvement in protein synthesis, and may
contribute to breast cancer progression.
ZNFX1-ANTISENSE RNA 1 (ZFAS1)
ZNFX1 antisenseRNA1 (ZFAS1) is an antisense lncRNA that over-
laps the promoter region of the gene ZNFX1, which encodes a zinc
ﬁnger protein whose exact role remains to be elucidated. ZFAS1
is host to three snoRNAs in three consecutive introns. ZFAS1 is
expressed in a wide variety of tissues, showing highest expres-
sion in the mammary gland and lung. It contributes to mammary
gland development, showing enrichment in the alveolar struc-
tures and ducts and differential expression during different stages
of pregnancy in mouse mammary glands. As well as acting as a
snoRNA host, Zfas1 has independent regulatory functions. Zfas1
is expressed in both the nucleus and cytoplasm, and knockdown
of cytoplasmic Zfas1 by siRNA in mouse mammary epithelial cell
lines increases proliferation. This suggests thatZfas1has dual func-
tions: after splicing in the nucleus to generate snoRNAs, Zfas1 is
transported to the cytoplasm where it regulates cellular prolifer-
ation. In addition to regulating mammary gland development,
ZFAS1 contributes to breast cancer, as its expression is reduced in
human ductal carcinoma compared to normal breast epithelium.
ZFAS1 plays a role in proliferation as well as differentiation, and its
down regulation may promote cancer progression, indicating that
it may have tumor suppressor functions (Askarian-Amiri et al.,
2011).
GROWTH ARREST-SPECIFIC 5 (GAS5 )
Long ncRNA growth arrest-speciﬁc 5 (GAS5) containing up to
12 exons was ﬁrst isolated from growth arrested NIH-3T3 cells,
induced upon serum starvation of cells (Schneider et al., 1988;
Raho et al., 2000). GAS5 contains a stem-loop structure at its 3′
end that resembles the double stranded GRE and is able to act
as a decoy for the GR, binding to it and sequestering it from its
DNA response element. GAS5 suppresses the transcription of GR
target genes, such as cIAP2, PEPCK, and G6Pase. These genes are
crucial for glucose metabolism, and thus GAS5 may function to
conserve energy resources in response to starvation (Kino et al.,
2010).
Growth arrest-speciﬁc 5 acts as a tumor suppressor gene in
breast cancer as its expression is signiﬁcantly reduced compared
to normal breast epithelium. It is a regulator of apoptosis as forced
overexpression in breast cancer lines induced apoptosis, sensitized
cells to apoptotic inducers and repressed proliferation (Mourtada-
Maarabouni et al., 2008). GAS5’s function as a tumor suppressor
gene is a combination of its two mechanisms of action. Decreased
expression of RNU44, a snoRNA derived from GAS5 is associated
with more aggressive tumors in breast cancer and head and neck
squamous cell carcinoma (Gee et al., 2011). Additionally, many
GR target genes are anti-apoptotic (Kino et al., 2010) and through
its inhibition, GAS5 promotes apoptosis.
ORGANIZING NUCLEAR STRUCTURES
The nucleus is highly organized into different domains, which
provide an essential basis for the complex regulation of nuclear
processes and gene expression. In addition to protein factors, some
of these subnuclear domains contain lncRNAs. These nuclear
lncRNAs are essential for nuclear regulation, with some acting
as structural scaffolds, while others directly modulate nuclear
compartment function. Nuclear organization is fundamental to
modulating the activities of the genome, and this can become
disrupted in cancer (Bergmann and Spector, 2014). In breast can-
cer, lncRNAs involved in organizing nuclear structures become
deregulated, and may drive cancer progression, as discussed
below.
LONG STRESS INDUCED NON-CODING TRANSCRIPT 5 (LSINCT5 )
Long stress induced non-coding transcript 5 (LSINCT5) is a
nuclear localized lncRNA that was discovered in screens to iden-
tify lncRNAs upregulated upon treatment with stress inducing
chemicals. In normal tissues, LSINCT5 is highly expressed in pro-
liferative and stress responsive tissues such as the colon and spleen
compared to non-proliferative tissues such as brain. Expression of
LSINCT5 is increased in several cancers, including breast and ovar-
ian cancer. Because of its high expression in proliferative tissues
and cancer, LSINCT5 could potentially function as a regulator
of proliferation. This is supported by LSINCT5 knockdown in
breast and ovarian cancer cell lines, which impairs proliferation
(Silva et al., 2011). Additionally, knockdown of LSINCT5 leads
to altered expression of several genes including suppression of
CXCR4, a breast cancer marker associated with metastasis, the
lncRNA NEAT1 and the protein coding gene PSPC1 (paraspeckle
component 1; Silva et al., 2011). LSINCT co-localizes with NEAT1
in the nucleus (Smith and Jessica, 2012), suggesting LSINCT5
regulates nuclear paraspeckle maintenance. How LSINCT5 con-
tributes to paraspeckle function is yet to be determined, and it
is possible that it acts to regulate proliferative genes in speciﬁc
nuclear bodies.
METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1
(MALAT1)
Metastasis associated lung adenocarcinoma transcript 1
(MALAT1) is a highly conserved, abundant lncRNA whose expres-
sion is localized to the nucleus. It was discovered in non-small cell
lung cancer as a prognostic marker of later metastasis (Ji et al.,
2003) but since then has been found in several other types of
human cancer, including breast cancer. MALAT1 expression is typ-
ically upregulated in cancer and has been associated with several
neoplastic phenotypic features including proliferation, cell death,
migration, invasion, and metastasis (reviewed in Gutschner et al.,
2013b).
Metastasis associated lung adenocarcinoma transcript 1 is
a core component of nuclear speckles, which are involved in
mRNA processing, splicing, and export (Hutchinson et al., 2007).
Blocking transcription causes a redistribution of MALAT1 from
the nuclear speckles to the nucleoplasm (Bernard et al., 2010),
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indicating that MALAT1 regulates active transcription or process-
ing. MALAT1 also localizes with several splicing factors, including
SRSF1–3 (Anko et al., 2012). MALAT1 depletion decreases the
association of these splicing factors with the nuclear speckles
and differential alternative splicing of pre-mRNA (Tripathi et al.,
2013). It is proposed that MALAT1 regulates the recruitment of
splicing factors to these pre-mRNAs. MALAT1 also regulates other
nuclear factors, such as polycomb group proteins. This lncRNA
binds to unmethylated Polycomb 2 protein (PC2) in response to
growth signals, shifting its location from repressive polycombbod-
ies on growth control gene loci to active interchromatin granules,
activating their expression. MALAT1 acts as a switch for polycomb
target genes from repressive nuclear domains to active nuclear
domains, inﬂuencing gene expression (Gutschner et al., 2013b).
Metastasis associated lung adenocarcinoma transcript 1 also
regulates expression of cell cycle genes. It is required for G1/S
transition and mitotic progression, and depletion of MALAT1
leads to cell cycle arrest and activates p53 and p53 target genes.
Additionally, cells depleted in MALAT1 show reduced expression
of B-MYB, an oncogenic transcription factor involved in G2/M
progression. MALAT1 regulates the cell cycle by modulating key
transcription factors which, when deregulated, could promote
cancer progression (Tripathi et al., 2013).
In breast cancer, MALAT1 is also upregulated (Guffanti et al.,
2009), although its function remains to be determined. MALAT1
harbors mutations and deletions in luminal breast cancer, in a
region which modulates interaction with the splicing factors 1–3
(SRSF1–3; Gutschner et al., 2013b). These mutations could alter
the function of MALAT1, leading to deregulated splicing events.
Treatment of breast cancer cells with high levels of estradiol
reduces MALAT1 transcription, reducing proliferation, migra-
tion, and invasion (Zhao et al., 2014). Although higher expression
of MALAT1 is associated with poorer outcomes in a number of
cancers, Sun et al. (2009) have shown that MALAT1 is decreased
in proliferating mammary glands of c-myc transgenic mice and
further decreased to undetectable levels in mammary tumors.
MALAT1 may regulate many genes, and its regulation is context
speciﬁc.
RIBOSOME ASSOCIATED lncRNAs
The advent of high throughput technologies is uncovering unex-
pected roles for lncRNAs. Ingolia et al. (2011) performed genome
wide ribosome proﬁling in mouse embryonic stem cells, a recently
developed technique that involves digesting RNA and sequenc-
ing the portion bound to the 80S ribosome to give a proﬁle of
ribosome occupancy. Unexpectedly, they discovered that a large
set of intergenic lncRNAs was bound to ribosomes, raising the
question of whether these lncRNAs were translated to small pro-
teins. In light of these ﬁndings, Guttman et al. (2013) revisited
these experimentswith a newmetric to discriminate between tran-
scripts that were being actively translated and those just bound to
the ribosome. During translation, ribosomes release their tran-
script upon encountering a stop codon, which is seen as a drop
in 3′UTR occupancy. As this should not occur for non-coding
transcripts, Guttman et al. (2013) developed a metric based on
ribosome release of these transcripts. What they found was that
even though a large number of long intergenic ncRNAs (lincRNA)
bind, they are not actively translated. This is not just restricted
to lincRNAs, as independent studies have also found a large pro-
portion of other classes of lncRNAs bound to actively translating
ribosomes (van Heesch et al., 2014).
As these lncRNAs have been conﬁrmed to not encode for pro-
teins, this raises the question of why so many lncRNAs are bound
to ribosomes. Few of these lncRNAs have been studied in detail,
but those that have been investigated have been found to regulate
translation by associating with polysomes during stress conditions
and either upregulating speciﬁc proteins, as is the case for Uchl1AS
(Carrieri et al., 2012), or globally inhibiting translation as formlon-
RNAs found in yeast (Galipon et al., 2013). Their roles in disease
processes have not been established. Here, we highlight ribosome
associated lncRNAs and discuss their putative roles in regulating
ribosome function in breast cancer.
TRANSLATIONAL REGULATORY lncRNA (TreRNA)
Translational regulatory lncRNA (TreRNA) was identiﬁed through
genome wide computational analysis (Orom et al., 2010) and
found to be upregulated in cellular invasion and tumor metastasis,
as well as upregulated in lymph node metastatic breast cancer
samples when compared to matched primary tumors. TreRNA is
also overexpressed in primary colon cancer samples compared to
healthy controls, indicating an associationbetween treRNA expres-
sion and cancer progression, including metastatic development
(Gumireddy et al., 2013).
Further evidence that treRNA promotes invasion and metasta-
sis has been obtained from in vitro and in vivo studies. Enforced
expression of treRNA in breast cancer cell lines and mouse models
signiﬁcantly promoted invasion and lung metastases, respectively,
whereas knockdown suppressed cellular migration, invasion, and
metastasis inmouse (Gumireddy et al., 2013).TreRNA also leads to
suppression of epithelial markers, which is associated with metas-
tasis and transition to a mesenchymal state. Enhanced treRNA
expression suppresses E-cadherin, and to a lesser extent zonula
occludens-1 (ZO-1) and β-catenin, and increases expression of
ﬁbronectin and vimentin (Gumireddy et al., 2013). This change
in cellular markers indicates a partial epithelial to mesenchymal
transition.
This lncRNA employs different mechanisms of action depend-
ing on its cellular location. In the nucleus, treRNA acts as an
enhancer for neighboring genes such as Snail (Orom et al., 2010).
Cytoplasmic treRNA on the other hand acts to regulate E-cadherin
by modulating its translation. Expression of treRNA reduces the
level of E-cadherin protein without affecting mRNA abundance,
and redistributes E-cadherin mRNA from high molecular weight
polysomes to low molecular weight polysomes, strongly indicating
that it suppresses translation of E-cadherin. How treRNA func-
tions to inhibit translation is yet to be known, but it is proposed
that treRNA promotes the formation of a ribonucleoprotein com-
plex with hnRNP K,FXR1, FXR2, PUF60, and SF3B. This treRNA–
protein complex may interact directly or indirectly with E-
cadherin mRNA to inhibit its translation (Gumireddy et al., 2013).
LncRNAs IN ESTROGEN SIGNALING
Estrogens are mitogens that promote cellular growth and pro-
liferation, and development of the mammary gland. Estrogens
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signal by binding to nuclear receptors that regulate gene transcrip-
tion. Mice lacking estrogen receptors cannot undergo pubertal
mammary glanddevelopment. Aberrant estrogen signaling partic-
ipates in breast cancer. Increased estrogen exposure may stimulate
excess proliferation and has been linked to higher rates of breast
cancer. 60–70% of breast cancers overexpress the estrogen recep-
tor and show increased responses to the mitogenic effects of
estrogen (reviewed in Manavathi et al., 2013). Estrogen directly
modiﬁes the expression of protein coding genes and also inter-
acts with certain lncRNAs to modify gene expression, as discussed
below.
H19
H19 is derived from a large imprinted locus on human chro-
mosome 11p15.5. This lncRNA is abundantly expressed in the
developing embryo, highly expressed in the mammary bud and
adjacent tissues and differentially regulated during mammary
gland development. H19 is expressed exclusively from the mater-
nal allele where it acts to regulate the expression of IGF2, the
paternally expressed growth factor from the same locus, by repress-
ing both its transcription (Wilkin et al., 2000) and translation
(Li et al., 1998). H19 is transcriptionally induced by the tran-
scription factor E2F1, which promotes cell cycle progression. Its
expression is repressed by pRB and E2F6, both of which are E2F-
dependent transcriptional inhibitors (Ratajczak, 2012). c-Myc,
which binds to E-box regions, also promotes transcription of H19
(Barsyte-Lovejoy et al., 2006). As H19 is under the transcriptional
control of two well-known oncoproteins, E2F1 and c-myc, it is
likely that it also participates in a network that promotes tumor
progression.
H19 expression is normally downregulated in normal adult
tissue, with only a few tissues, including the mammary gland,
showing basal expression. In mouse mammary glands H19
expression is repressed during prepubertal development, upreg-
ulated during both puberty and pregnancy, repressed during
lactation and then once again upregulated during involution
indicating that it is not necessary for terminal differentiation
but may instead function in proliferation, migration, and pre-
terminal differentiation (Ratajczak, 2012). H19 is upregulated
in breast cancer, with over 70% of breast adenomas show-
ing overexpression, and is signiﬁcantly correlated with ER+
and PR+ breast cancers (Adriaenssens et al., 1998). Estradiol
transcriptionally regulates H19, as treatment with estradiol of
ovariectomized and adrenalectomized mice increases H19 expres-
sion in the uterus, as well as increasing its expression in breast
cancer cell lines (Adriaenssens et al., 1999). Transfection of
H19 in breast cancer cells also increases their ability to form
tumors when injected into mice (Lottin et al., 2002) and its
overexpression leads to an increase in breast cancer prolifer-
ation by increasing entry into S phase, whereas knockdown
prevented cell cycle progression through S phase (Berteaux et al.,
2005).
SOX2 OVERLAPPING TRANSCRIPT (SOX2OT )
SRY (sex determining region Y)-box 2 (SOX2) is a transcription
factor that acts a key regulator of pluripotency and lies within
the intron of a lncRNA, called SOX2OT. SOX2 is required for
embryonic stem cell self-renewal and pluripotency and is often
deregulated in cancer (Liu et al., 2013). SOX2OT is a stable tran-
script, which, like SOX2, is expressed in embryonic stem cells and
downregulated upon induction of embryoid body differentiation.
SOX2OT is dynamically regulated during embryogenesis of sev-
eral vertebrates, and restricted to the brain in adult mouse and
humans (Amaral et al., 2009).
In breast cancer, SOX2 overexpression is observed in aggres-
sive tumors and associated with a stem cell like phenotype and
SOX2OT plays a key role in regulating SOX2. Expression of both
SOX2 and SOX2OT are positively correlated in breast cancer
samples, with ER+ tumors showing greater expression of both
genes than ER− tumors, suggesting that this lncRNA is sensi-
tive to steroid hormones such as estrogens. Ectopic expression of
SOX2OT induced SOX2 expression, suggesting a positive regula-
tory role for SOX2OT. Orthotopic xenografts of breast cancer cells
also show upregulation of both SOX2 and SOX2OT (Askarian-
Amiri et al., 2014). SOX2OT not only regulates SOX2 in vertebrate
development, but also regulates SOX2 during disease processes
such as cancer.
LncRNAs AND DRUG RESISTANCE
Survival rates of patients with breast cancer have signiﬁcantly
improved over the past several decades. While many factors are
credited for this more positive outlook, including early detection
methods, this improvement can also be attributed to new treat-
ment programs as well as the development of new drugs. However,
continuous chemotherapy often leads to drug resistance, hinder-
ing the long-term control of cancers. Chemoresistance is often
reported to be a result of increase in efﬂux transporters or deregu-
lation of signaling pathways, and there is increasing evidence that
epigenetic factors contribute to drug resistance. In the following
section lncRNAs that contribute to drug resistance in breast cancer
will be discussed.
ADRIAMYCIN RESISTANCE ASSOCIATED (ARA)
Doxorubicin, also known as Adriamycin, is a chemotherapeutic
drug that acts as a topoisomerase II poison. It is used to treat
a variety of cancers, including breast cancer (Cortes-Funes and
Coronado, 2007). However, prolonged exposure to doxorubicin
induces drug resistance, making the cancer harder to treat. Jiang
et al. (2014) recently identiﬁed several lncRNAs including ARA
that showed differential expression in doxorubicin resistant breast
and liver cancer cell lines. This lncRNA is derived from the intronic
region of the PAK3 gene, and is upregulated in doxorubicin resis-
tant MCF7 cells compared to the parental cell line. Treatment of
sensitive breast cancer cell lines with doxorubicin led to an increase
in ARA expression, and thus prolonged exposure to doxorubicin
may lead to constant upregulation of ARA during the initiation
of drug resistance. ARA may also be involved in self-sufﬁciency
in estrogen signaling, as estrogen receptor negative breast cancer
cell lines expressed greater levels of ARA than estrogen receptor
positive cell lines.
Silencing of ARA in doxorubicin resistant breast cancer cell
lines restored sensitivity to doxorubicin, as well as inhibiting
cellular proliferation, inducing apoptosis and the accumulation
of cells in the G2/M phase and reducing cell motility. Genes
www.frontiersin.org October 2014 | Volume 5 | Article 379 | 9
Hansji et al. LncRNAs in breast cancer
Table 1 | List of lncRNAs involved in breast cancer progression with their proposed functions.
LncRNA Expression in
breast cancer
Mechanism of action Effect on breast cancer progression
ARA Upregulated in
doxorubicin
resistant breast
cancer cells
Unknown, but it may initiate doxorubicin resistance,
perhaps through MAPK, PPAR, focal adhesion and
metabolism signaling pathways
Silencing of ARA increases sensitivity to doxorubicin,
inhibits cellular proliferation, induces apoptosis, reduces
cell motility
BC200 Upregulated Sequesters PABP, preventing protein synthesis Promotes aggressive cell behavior, as expressed only in
invasive tumors
GAS5 Downregulated •Acts as a decoy for GRE and sequesters GR
•Host for several snoRNAs
Resistance to apoptosis
H19 Upregulated Unknown, but may be involved in cell cycle progression
as it is induced by E2F1 and c-Myc
•Promotes tumor growth when transfected cells are
injected into mice
•Increases entry into S phase of cell cycle
HOTAIR Upregulated •Trimethylation of histone H3K27 by recruiting PRC2 to
HOXD locus
•Demethylation of H3K4 by binding to LSD1 at HOXD
locus
•Competitive inhibitor of BRCA1 binding to EZH2
•Silences PTEN through methylation
•Increased invasion in vitro
Increased metastasis in vivo
•Predictor of poor prognosis
LSINCT5 Upregulated Localizes with NEAT1 and regulates nuclear paraspeckles Increases cellular proliferation in response to stress
MALAT1 Upregulated •Regulates active transcription
•Recruits splicing factors
•Regulates expression of cell cycle genes
•Modulates cellular location of PC2
Unknown, but in other cancers, overexpression increases
cell motility and migration, and acts as a predictor for
metastasis
SOX2OT Upregulated Induces SOX2 expression Unknown, but may promote EMT through induction of
SOX2
SRA1 Upregulated Binds to corepressors and coactivators to modulate
activity of estrogen receptor
Increases cellular proliferation by activating estrogen
receptor
TreRNA Upregulated •Nuclear treRNA acts an enhancer for Snail transcription
•Cytoplasmic treRNA inhibits the translation of
E-cadherin, possibly through formation of a
ribonucleoprotein complex with hnRNP K, FXR1, FXR2,
PUF60 and SF3B
Promotes invasion and metastasis, through regulation of
Snail and E-cadherin, may promote
epithelial-mesenchymal transition
UCA1 Upregulated Competes with p27 for binding to hnRNP-1, preventing
p27 translation
Increases breast cancer growth by promoting cell cycle
progression
XIST Downregulated •X chromosome inactivation to form Barr body
•May interact with BRCA1 but mechanism unknown
Loss of XIST could be a result of genetic instability,
tumors that lose XIST are highly aggressive
regulated by ARA are enriched in several pathways, including
MAPK, focal adhesion, PPAR, and metabolism signaling path-
ways. ARA may contribute a survival and proliferative advantage
to doxorubicin resistant cells, and inhibition of ARA returns the
breast cancer cell to the parental drug sensitive phenotype (Jiang
et al., 2014).
UROTHELIAL CARCINOMA-ASSOCIATED 1 (UCA1)
Urothelial carcinoma-associated 1 (UCA1) was originally
identiﬁed as being dramatically upregulated in bladder cancer, and
is known as a highly speciﬁc and sensitive biomarker for diagnos-
ing bladder carcinoma (Wang et al., 2008). UCA1 expression is
elevated in embryonic tissues, then turned off in most tissues after
birth. It is reactivated in cancer, indicating thatUCA1 is an oncofe-
tal gene (Wang et al., 2008). In breast cancer, UCA1 is upregulated
and displays oncogenic properties. In vitro, ectopic expression of
UCA1 enhances breast cancer cell growth,whileUCA1-siRNAsup-
presses growth, leading to the accumulation of cells in G1 phase,
as well as decreased Ki67 staining in tumors from mice (Huang
et al., 2014). An isoform of UCA1 is associated with doxorubicin
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resistance in a squamous cell carcinoma line (Tsang et al., 2007),
but it is not known whether this applies to breast cancer.
Urothelial carcinoma-associated 1 forms a ribonucleopro-
tein complex with heterogeneous nuclear ribonucleoprotein 1
(hnRNP-1). Its expression is mainly restricted to the nucleus,
where it plays a key role in the splicing of pre-mRNA (Izquierdo
et al., 2005), but low levels are also expressed in the cytoplasm.
In the cytoplasm, hnRNP1 acts as an activator of translation.
By binding to the 5′ UTR of mRNA, hnRNP recruits ribo-
somal proteins to initiate translation of several mRNAs such
as that of p27, a well-known tumor suppressor protein that
inhibits cyclin-dependent kinases. UCA1 inhibits the interaction
between the p27 mRNA and hnRNP, preventing the transla-
tion of p27. Thus, there exists a competition between p27
and UCA1, as indicated by a decrease in p27 mRNA and
hnRNP complex when UCA1 is overexpressed. Additionally,
although both UCA1 and p27 mRNA interact with hnRNP1,
they are present as separate hnRNP complexes, perhaps indi-
cating that they compete for the same binding site, or that
binding of either RNA in an allosteric site induces a conforma-
tional change that prevents binding of the other (Huang et al.,
2014).
LncRNAs AS POTENTIAL THERAPEUTIC TARGETS
As discussed in this review, several lncRNAs have been implicated
in cancer and modulation of these lncRNAs could lead to new
therapeutic advances for cancer treatment.
Long ncRNAs can be targeted byRNA interference technologies
such as siRNAs and shRNAs. These molecules show a high degree
of selectivity and knockdown efﬁciency and could therefore be
used to silence lncRNAs for treatment of disease. Although the use
of siRNA and shRNA for therapeutic use is still in development,
a few siRNAs have been used in clinical trials for a number of
diseases, including cancer (Burnett et al., 2011). Various chemical
modiﬁcations can also improve the stability and delivery of these
RNA targeting molecules, which would be valuable if they were
to be used in a clinical setting to target critical lncRNAs (Lorenz
et al., 2004).
Other strategies that could be used to target lncRNAs include
antisense oligonucleotides (ASO), single stranded DNA or RNA
molecules with a speciﬁc sequence designed to target a partic-
ular RNA. ASOs bind to their target RNAs with high sequence
speciﬁcity, and induce their degradation by RNAse H1. They have
been used experimentally to inhibit MALAT1 in cancer cells and
subcutaneous tumors in nude mice (Gutschner et al., 2013a) with
success. ASOs could be designed to target other lncRNAs which
act as oncoRNAs so as to inhibit their expression.
Long ncRNAs have also been proposed as potential biomark-
ers for cancer progression. As discussed previously, HOTAIR and
BC200 are upregulated in breast cancer as well as in other cancers.
High expression of HOTAIR is correlated with poor survival in
breast cancer, increased recurrence of hepatocellular carcinoma
following surgical hepatectomy, and high grades of gastrointesti-
nal stromal tumor (GIST; Gupta et al., 2010; Niinuma et al., 2012;
Ishibashi et al., 2013). HOTAIR and BC200 (Iacoangeli et al., 2004)
may be useful to predict patient outcome and tumor aggressiveness
in breast cancer.
However, therapeutic use of lncRNAs is not without its lim-
itations. New tools will be needed to study their function, of
which RNA interference technologies will be vital. Neverthe-
less, identifying the mechanism of lncRNAs will require exten-
sive characterization of individual cases. These studies will also
need to address the biological context of lncRNAs, as lncRNAs
might regulate different functions in different tissues or disease
processes.
Long ncRNAs are expressed at low abundance compared to
protein coding genes, which can make functional studies chal-
lenging. However, this may be due to their expression in only
small subpopulations of cells, providing highly speciﬁc targets
for disease therapy (Djebali et al., 2012). LncRNAs show con-
served function and structure in different species, and despite
their poor sequence conservation could potentially be targeted
for drug therapy. However, extrapolating results in animal models
to humans must be done with care, especially for those lncRNAs
whose roles dependon their sequence conservation such asmiRNA
decoys.
LncRNAs are active in multiple levels of gene regulation. They
play important roles in the human mammary gland development
and breast carcinogenesis. Several studies have examined their
role as therapeutic targets and it is possible that lncRNAs could be
targeted clinically in the future.
CONCLUDING REMARKS
Long ncRNAs are important regulators of gene expression and
have a wide variety of functions that enable them to interact
with multiple pathways that modulate breast cancer progressions.
These lncRNAs have been shown to act as oncoRNAs, often
upregulated in breast cancer and facilitating tumor growth and
progression, or acting as tumor suppressors, showing downreg-
ulation in breast cancer and inhibiting tumorigenesis (Table 1).
Their role as therapeutic agents is currently being explored, and
highly speciﬁc lncRNA expression signatures make them attrac-
tive markers for accurate disease diagnostics. As well as their
use for diagnosis and prognosis, the advancement of RNA-based
therapeutics opens up lncRNAs as new targets for therapy. The
functional role of the plethora of lncRNAs is only beginning
to be elucidated, and provides an untapped resource for the
development of cancer therapies and biomarkers.
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